Andrea Cercek, MD

Experts provide advice for providers treating patients with metastatic colorectal cancer and highlight exciting potential combination treatments on the horizon.

Dr Andrea Cercek reviews key clinical trials in HER2-amplified colorectal cancer treatment and considers how the approval of new therapies will impact the current treatment landscape.

Andrea Cercek, MD, explains the potential treatment options for metastatic colorectal cancer after disease progression.

Dr Jaclyn Hechtman presents the profile of a patient with HER2+ metastatic colorectal cancer and has a conversation with Dr Andrea Cercek on how to personalize frontline therapy selection in each patient.

A look at how the molecular testing landscape in colorectal cancer is evolving.

Drs Hechtman and Cercek discuss how practice setting affects molecular testing options and the barriers patients face in receiving testing.

Experts describe which patients should be screened for HER2 amplification in colorectal cancer and how best to detect it.

A pathologist explains how she chooses between a variety of molecular testing technology options in colorectal cancer.

Jaclyn Hechtman, MD, provides an overview of the history of molecular testing in colorectal cancer and how testing has evolved.

Andrea Cercek, MD, discusses targeted strategies in BRAF-mutant metastatic colorectal cancer.

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the impact of tumor sidedness on frontline treatment decisions in metastatic colorectal cancer (mCRC).

Andrea Cercek, MD, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC).

Andrea Cercek, MD, discusses the importance of molecular testing in colorectal cancer.

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chemotherapy resistance in mismatch repair deficient rectal cancer.

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses induction chemotherapy in patients with mismatch repair deficient rectal cancer.